Aclaris Therapeutics, Inc.
NASDAQ•ACRS
CEO: Dr. Neal S. Walker D.O., M.D.
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 2015-10-06
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Contact Information
Market Cap
$434.14M
P/E (TTM)
-6.9
28.2
Dividend Yield
--
52W High
$4.89
52W Low
$1.05
52W Range
Rank45Top 56.8%
3.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$1.30M+0.00%
4-Quarter Trend
EPS
-$0.16+0.00%
4-Quarter Trend
FCF
-$13.09M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Net Loss Significantly Narrowed Net loss reduced to $64.9 M USD in 2025, down $67.1 M from prior year's $132.1 M loss.
R&D Investment Increased Research and development expenses increased $19.1 M to $52.6 M USD supporting key pipeline assets development.
Bosakitug Phase 2a Strong Results Bosakitug Phase 2a showed 94% patients achieved EASI-75 improvement in moderate to severe atopic dermatitis.
ATI-052 Phase 1 Positive Data ATI-052 announced positive interim Phase 1a/1b results in January 2026, planning Phase 2b trials H2 2026.
Risk Factors
Continued Operating Losses Expected Incurred $64.9 M net loss in 2025; expect continued operating losses requiring substantial future capital infusion.
Substantial Capital Needs Substantial additional funding required; inability to raise capital forces curtailment of planned operations immediately.
Reliance on Third Parties Heavy reliance on third parties for clinical trials and manufacturing introduces performance and supply chain risks.
AI Risks to Platform Rapid AI advancement risks making proprietary KINect platform less competitive or obsolete, impacting competitive position.
Outlook
Seek Third-Party Partnerships Intend to identify and consummate transactions with third-party partners for further product development and approval.
Bosakitug Data Expected 2026 Expect top-line data announcement for Bosakitug Phase 2 trial in second half of 2026 for respiratory indications.
Advance ITK and Bispecific Programs Plan IND filing for ATI-2138 in H2 2026; expect Phase 2b trials for ATI-052 in H2 2026.
Continue KINect Discovery Efforts Continue small molecule drug discovery efforts leveraging proprietary KINect platform targeting difficult kinases for novel assets.
Peer Comparison
Revenue (TTM)
$2.76B
$727.33M
$445.38M
Gross Margin (Latest Quarter)
162.0%
96.7%
94.3%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| ALLO | $591.04M | -2.8 | -57.8% | 19.4% |
| ACRS | $434.14M | -6.9 | -52.0% | 1.3% |
| CABA | $314.79M | -2.1 | -107.1% | 13.6% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-3.8%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Deep Research
Next earnings:May 6, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data